[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BG101408A - Аналози на кератиноцитния растежен фактор - Google Patents

Аналози на кератиноцитния растежен фактор

Info

Publication number
BG101408A
BG101408A BG101408A BG10140897A BG101408A BG 101408 A BG101408 A BG 101408A BG 101408 A BG101408 A BG 101408A BG 10140897 A BG10140897 A BG 10140897A BG 101408 A BG101408 A BG 101408A
Authority
BG
Bulgaria
Prior art keywords
analogs
growth factor
keratinocyte growth
kgf
epithelial cell
Prior art date
Application number
BG101408A
Other languages
English (en)
Other versions
BG63167B1 (bg
Inventor
Charles Morris
William Kenney
Bao-Lu Chen
Erik Hsu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of BG101408A publication Critical patent/BG101408A/bg
Publication of BG63167B1 publication Critical patent/BG63167B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретението се отнася до аналози на силен митоген на растежа на нефибробластни епителни клетки, кератиноцитен растежен фактор (KGF), модифициран допървите 24 N-крайни аминокиселини, където цистеиновите остатъци, съответстващи на позициите на аминокиселини 1 и 15 на KGF [позиции 32 и 46 на аминокиселини от SEQ ID NO:2, (съответно Cys1 и Cys15)],са заличени или заместени с друга аминокиселина. Изобретението се отнася и до молекули на нуклеинови киселини, които кодират такива аналози, и до методи за използването на такива аналози за стимулиране пролиферацията на нефибробластни епителни клетки.
BG101408A 1994-10-13 1997-04-11 Аналози на кератиноцитния растежен фактор BG63167B1 (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000971 WO1996011949A2 (en) 1994-10-13 1995-10-12 Analogs of keratinocyte growth factor

Publications (2)

Publication Number Publication Date
BG101408A true BG101408A (bg) 1997-12-30
BG63167B1 BG63167B1 (bg) 2001-05-31

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
BG101392A BG101392A (bg) 1994-10-13 1997-04-07 Метод за лечение на захарен диабет с използване на кератиноцитен растителен фактор
BG101408A BG63167B1 (bg) 1994-10-13 1997-04-11 Аналози на кератиноцитния растежен фактор

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BG101392A BG101392A (bg) 1994-10-13 1997-04-07 Метод за лечение на захарен диабет с използване на кератиноцитен растителен фактор

Country Status (23)

Country Link
EP (2) EP0804479B1 (bg)
JP (2) JP4216329B2 (bg)
KR (1) KR100278597B1 (bg)
CN (1) CN1168678A (bg)
AT (2) ATE237633T1 (bg)
AU (1) AU3707795A (bg)
BG (2) BG101392A (bg)
BR (2) BR9509329A (bg)
CA (2) CA2201940C (bg)
CZ (3) CZ297329B6 (bg)
DE (2) DE69535264T2 (bg)
DK (2) DK0804479T3 (bg)
EE (2) EE9700225A (bg)
ES (2) ES2196082T3 (bg)
FI (2) FI971420A0 (bg)
HU (2) HUT78050A (bg)
NO (2) NO971566L (bg)
NZ (2) NZ505502A (bg)
PL (2) PL320484A1 (bg)
PT (2) PT785948E (bg)
SI (2) SI0785948T1 (bg)
SK (2) SK284534B6 (bg)
WO (2) WO1996011949A2 (bg)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022681B (en) 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
DK0706563T3 (da) 1993-06-29 2005-01-31 Chiron Corp Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet
PT785949E (pt) * 1994-10-13 2003-09-30 Amgen Inc Metodo para purificar factores de crescimento de queratinocitos
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
DK0822943T3 (da) * 1995-04-27 1999-11-29 Cooperatie Cosun U A Inulinderivater
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ES2218666T3 (es) * 1996-10-15 2004-11-16 Amgen Inc., Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2).
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1041996A4 (en) 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
MXPA03006988A (es) * 2001-02-06 2003-11-18 Merck Patent Gmbh Factor de crecimiento de queratinocitos (kgf) modificado con inmunogenicidad reducida.
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
AU2002326742B2 (en) * 2001-08-21 2007-05-31 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
EP1827483B1 (en) 2004-12-15 2014-07-02 Swedish Orphan Biovitrum AB (publ) Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
GEP20022681B (en) * 1989-01-31 2002-04-25 Aaronson Us Stuart A Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
IL109122A (en) * 1993-03-26 2004-07-25 Amgen Inc Use of products from a keratinocytic growth factor for the preparation of medicinal preparations
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
DK0706563T3 (da) * 1993-06-29 2005-01-31 Chiron Corp Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
WO1995003831A1 (en) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Monogenous preparations of cytotoxic conjugates

Also Published As

Publication number Publication date
PT804479E (pt) 2007-02-28
NO971568L (no) 1997-06-12
DK0804479T3 (da) 2007-01-29
BR9509269A (pt) 1997-12-23
AU3708395A (en) 1996-05-06
DE69530403T2 (de) 2003-10-30
HUT78050A (hu) 1999-07-28
ATE342278T1 (de) 2006-11-15
DK0785948T3 (da) 2003-08-04
CA2201940A1 (en) 1996-04-25
HU226168B1 (en) 2008-05-28
SK43197A3 (en) 1999-03-12
FI971536A0 (fi) 1997-04-11
NO318761B1 (no) 2005-05-02
CZ105097A3 (cs) 1998-10-14
BG101392A (bg) 1997-10-31
CZ98197A3 (cs) 1998-11-11
PL319784A1 (en) 1997-08-18
CA2202075A1 (en) 1996-04-25
SI0785948T1 (en) 2003-08-31
AU681546B2 (en) 1997-08-28
ES2273338T3 (es) 2007-05-01
WO1996011950A1 (en) 1996-04-25
CZ297328B6 (cs) 2006-11-15
NZ505502A (en) 2005-01-28
DE69535264D1 (de) 2006-11-23
EE03975B1 (et) 2003-02-17
FI971536A (fi) 1997-06-09
KR100278597B1 (ko) 2001-01-15
JP4216329B2 (ja) 2009-01-28
CA2201940C (en) 2009-05-12
ES2196082T3 (es) 2003-12-16
NO971566L (no) 1997-04-14
SK284534B6 (sk) 2005-06-02
FI971420A (fi) 1997-04-04
EP0804479B1 (en) 2006-10-11
PL320484A1 (en) 1997-09-29
BR9509329A (pt) 1997-10-14
EP0785948A1 (en) 1997-07-30
JPH10507193A (ja) 1998-07-14
HUT78058A (hu) 1999-07-28
JP4426646B2 (ja) 2010-03-03
FI971420A0 (fi) 1997-04-04
CZ297329B6 (cs) 2006-11-15
DE69535264T2 (de) 2007-02-01
WO1996011949A2 (en) 1996-04-25
SI0804479T1 (sl) 2006-12-31
WO1996011949A3 (en) 1996-12-12
FI120040B (fi) 2009-06-15
EP0785948B1 (en) 2003-04-16
NO971568D0 (no) 1997-04-04
JPH10507080A (ja) 1998-07-14
SK45597A3 (en) 1999-02-11
CA2202075C (en) 2003-12-09
ATE237633T1 (de) 2003-05-15
BG63167B1 (bg) 2001-05-31
AU3707795A (en) 1996-05-06
EE9700225A (et) 1998-02-16
CN1168678A (zh) 1997-12-24
EE9700081A (et) 1997-10-15
DE69530403D1 (de) 2003-05-22
NZ335109A (en) 2000-08-25
NO971566D0 (no) 1997-04-04
PT785948E (pt) 2003-09-30
PL182888B1 (pl) 2002-03-29
EP0804479A1 (en) 1997-11-05

Similar Documents

Publication Publication Date Title
BG101408A (bg) Аналози на кератиноцитния растежен фактор
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
AU7550098A (en) System for expressing hyperthermostable protein
BR9712077A (pt) Expressão de proteìnas de alto nìvel
CA2094027A1 (en) Osteogenic peptides
EP0546110A4 (en) New insulin-like growth factor binding protein igfbp-5
DK1396542T3 (da) P-selectin ligand protein
SI0785950T1 (en) Keratinocyte growth factor analogs
KR920004419A (ko) 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
Lai Studies on the structure of rabbit muscle aldolase: Determination of the primary structure of the COOH-terminal BrCN peptide; the complete sequence of the subunit polypeptide chain
EP0546074A4 (en) Genetic material encoding igfbp-5
YU172185A (en) Process for obtaining monoclonic anti-bodies
GB8821785D0 (en) Peptide compounds
EP0546087A4 (bg)
ATE291088T1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
EP0330700A4 (en) Human prourokinase-like polypeptide.
EP0750040A3 (en) Macrophage stimulating protein variant and method for producing the same
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
DE59207008D1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
ES8801378A1 (es) Un metodo para preparar un vector de expresion que tiene un sistema de replicacion funcional en un microorganismo hospedante
EP1295943A4 (en) POLYPEPTIDES CAPABLE THE POWER TO STIMULATE NEUTROPHILES
WO1999043834A3 (en) P-selectin ligand protein, including tetrameric fusion proteins
NZ606260A (en) Novel polypeptides involved in immune response